INDICATION & LIMITATION OF USE
DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Please see below for Important Safety Information for DESCOVY.
PrEP use can be long term1
A real-world study looked at ~14,000 people* who received PrEP care during a 6-year period1
(July 2012-March 2019; N=13,906)
Individuals engaged with PrEP care at any point during the retrospective study period1:
52.2% of those initiating PrEP discontinued at least once during the study
60.2% of those who discontinued reinitiated PrEP before the end of follow-up
(Hojilla JC, et al; 2017. Study used electronic health records from Integrated Health in Northern California)
*Prescriptions were filled for FTC/TDF or FTC/TAF for individuals aged ≥18 years with an indication for PrEP.
PrEP was first approved by the FDA in 2012. DESCOVY FOR PrEP® was approved in October 2019.2
When prescribing a potential long-term medication, such as PrEP, consider that3:
- Renal function may change over time
- Bone density is crucial for individuals of any age
of oral PrEP users had ≥1 renal or bone risk factor
in a retrospective study analyzing EHR data of over 40,000 people prescribed oral PrEP between 01/01/2015 and 02/29/2020.3